Bruker Launches Novel 7 Tesla and 9.4 Tesla Preclinical MRI Magnets
May 09 2022 - 12:52PM
Business Wire
Maxwell™ Preclinical MRI Magnets Do Not
Require Liquid Helium, Facilitate Siting
At the ISMRM 2022 conference, Bruker today announced the launch
of innovative 7 Tesla and 9.4 Tesla conduction-cooled Maxwell
magnets for its market-leading preclinical magnetic resonance
imaging (MRI) systems portfolio. Following the success of its
BioSpec® Maxwell 3 Tesla model, the new range of Maxwell 7 Tesla
and 9.4 Tesla magnets eliminates the need for liquid Helium or
Nitrogen refills, while offering high-field sensitivity and
resolution for advanced preclinical MRI and PET/MR research.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220509005888/en/
BioSpec Maxwell preclinical MRI system
(Photo: Business Wire)
The new BioSpec Maxwell MRI portfolio incorporates
high-performance technology into easy to use systems for a range of
preclinical applications, with simplified siting, installation and
maintenance, as typically no building modifications are necessary.
The systems offer a small-footprint and low maintenance that
combines touchscreen ease of use with full MR imaging
flexibility.
Preclinical imaging for non-invasive in vivo imaging on small
rodents provides researchers with high spatial and temporal
resolution in research applications including oncology, neurology,
cardiology and infectious diseases. The high stability of Bruker
MRI systems creates sharp and clean images, critical when examining
minuscule areas in high-resolution anatomical imaging of mouse
brains, or when performing functional MRI (fMRI).
The smart BioSpec Maxwell magnet technology features
reliable supervision with multiple built-in sensors. In the event
of a power outage or cooling disruption the Maxwell magnets remain
at field for a minimum of six hours, and can be auto-cooled and
auto-charged via push button operation.
Dr. Tim Wokrina, MRI Product Manager at Bruker PreClinical
Imaging Division, said: “We have achieved a significant milestone
in preclinical MRI technology, expanding its benefits to a wider
range of medical and pharmaceutical research to drive scientific
and therapeutic advancement.”
Dr. Wulf I. Jung, President of Bruker BioSpin’s PreClinical
Imaging Division, added: “The pharmaceutical industry is
experiencing pressure to bring new drugs to market faster and more
cost-effectively. Contract research organisations are striving for
best-in-class solutions in a small footprint. Our new Biospec
Maxwell MRI series does not require specialized lab infrastructure
and offers compact, light-weight and easy-to-install systems for
preclinical MRI or PET/MR studies.”
The new Maxwell conductively-cooled magnet technology is
available at three field strengths for different requirements: 3
Tesla, 7 Tesla, and 9.4 Tesla, all with 17 cm bore diameter,
high-performance gradient systems, and options to add a PET
accessory for PET/MR research. For more information, visit Bruker
preclinical imaging. Bruker preclinical imaging systems are for
research use only (RUO).
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. For more information, please visit:
www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220509005888/en/
Media Contact: Dr. Thorsten Thiel Bruker BioSpin VP of
Group Marketing T: +49 721 5161-6500 E: pr@bruker.com
Investor Relations Contact Justin Ward Sr. Director
Investor Relations & Corp Development T: +1 (978) 663–3660,
ext. 1479 E: Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Apr 2024 to May 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From May 2023 to May 2024